106 related articles for article (PubMed ID: 3784611)
1. Protocol design for lymphokine testing in clinical studies of human cancer.
Lotze MT; Rosenberg SA
Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cells: in vitro and in vivo studies.
Mazumder A
Lymphokine Res; 1985; 4(3):215-20. PubMed ID: 3897730
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg SA
Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
Kedar E; Chriqui-Zeira E; Kyriazis AP
J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
[TBL] [Abstract][Full Text] [Related]
6. Immunological monitoring of clinical trials using biological response modifiers.
Maluish AE
Lymphokine Res; 1986; 5 Suppl 1():S183-7. PubMed ID: 3784612
[TBL] [Abstract][Full Text] [Related]
7. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
10. Cancer therapy by biological response modifiers.
Herberman RB
Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
[TBL] [Abstract][Full Text] [Related]
11. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
12. Preclinical predictors of clinical safety: opportunities for improvement.
Sistare FD; DeGeorge JJ
Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
14. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
15. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
Dang Y; Disis ML
Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
[TBL] [Abstract][Full Text] [Related]
16. Genetically marking human cells--results of the first clinical gene transfer studies.
Cai Q; Rubin JT; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):125-36. PubMed ID: 7621260
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
18. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
Gomez GG; Hutchison RB; Kruse CA
Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
[TBL] [Abstract][Full Text] [Related]
19. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]